Brief: Xintela Gets Product Patent In USA For Chondrocyte-Based Products
15/08/2023 15:56
Aug 15 (Reuters) - Xintela AB XINT.ST :
* XINTELA GETS PRODUCT PATENT IN USA FOR CHONDROCYTE-BASED
PRODUCTS
* HAS ISSUED COMPANY'S PATENT APPLICATION ON
CHONDROCYTE-BASED
CELL THERAPY PRODUCTS, WITH VALIDITY THROUGH 2039
Source text for Eikon: ID:nMFN93Ml18
Further company coverage: XINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Xintela AB
See all newsBrief: Xintela To Raise SEK 30 Mln Via Convertible Loan From Flerie Invest
Advisory: Alerts on Xintela's phase I/IIa XSTEM results withdrawn
Brief: Xintela Q1 2026 Loss Before Tax SEK 11.8 Mln
Brief: Xintela Study Finds XSTEM Treatment Safe, Well Tolerated
Brief: Xintela Gets U.S. Patent For Xstem Treatment Of Difficult-To-Heal Wounds, Skin Defects